Bioage Labs Analyst Price Targets - Benzinga

Bioage Labs Inc

BIOANASDAQ

Trade with Public

Trade with Public

$5.57

-0.37-6.23%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

Bioage Labs Analyst Price Targets - Benzinga

Bioage Labs Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bioage Labs (BIOA).

Price Target Range — 7 Quarters

Analyst Consensus — 9 Analysts

7Buy

2Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$41Upside to Avg. PT+632.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	UBS	Alice Nettleton	Initiate	Neutral	$8
Sep 9, 2026	Roth Capital	Adam Walsh	Maintained	Buy	$25
Sep 8, 2026	BTIG	Thomas Shrader	Maintained	Buy	$40
Aug 6, 2026	BTIG	Thomas Shrader	Maintained	Buy	$40
Aug 3, 2026	BTIG	Thomas Shrader	Maintained	Buy	$40
Jul 31, 2026	Needham	Joseph Stringer	PT Cut	Buy	$50→$35
May 27, 2026	Roth Capital	Adam Walsh	Initiate	Buy	$36
May 13, 2026	BTIG	Thomas Shrader	Initiate	Buy	$40
Mar 27, 2026	Needham	Joseph Stringer	Initiate	Buy	$50
Mar 10, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$15→$52
Feb 25, 2026	Oppenheimer	Jay Olson	Initiate	Outperform	$60
Feb 18, 2026	Jefferies	Roger Song	Upgrade	Hold→Buy	$9→$62
Jan 27, 2026	Piper Sandler	Yasmeen Rahimi	Initiate	Overweight	$73
Dec 8, 2025	Morgan Stanley	Jeffrey Hung	Upgrade	Underweight→Equal-Weight	$5→$12
Oct 29, 2025	Citigroup	Samantha Semenkow	PT Raise	Buy	$10→$15
Oct 22, 2025	Citigroup	Samantha Semenkow	Upgrade	Neutral→Buy	$5→$10
Mar 24, 2025	Citigroup	Samantha Semenkow	PT Cut	Neutral	$7→$5
Mar 7, 2025	Morgan Stanley	Jeffrey Hung	Assumes	Underweight	$5
Feb 28, 2025	William Blair	Andy Hsieh	Initiate	Market Perform	—
Dec 9, 2024	Citigroup	Samantha Semenkow	Downgrade	Buy→Neutral	$45→$7

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8

UBS analyst Alice Nettleton initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Neutral rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Roth Capital Reiterates Buy on Bioage Labs, Maintains $25 Price Target

Roth Capital analyst Adam Walsh reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target

BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target

BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target

BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Bioage Labs, Lowers Price Target to $35

Needham analyst Joseph Stringer maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the price target from $50 to $35.

Benzinga Newsdesk